Where Women Veterans Seek Emergency Care: Patterns and Predictors of VA and Community Emergency Department Use - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Emergency Department Use Among Women Veterans: Patterns and Factors Associated With VA and Community Care

  • By

  • Jessica Faiz

  • Christopher J. Carvalho

  • Tracy Urech

  • Siqi Wu

  • Jessica Y. Breland

  • Susan M. Frayne

  • Donna L. Washington

  • Kristina M. Cordasco

  • Anita A. Vashi

  • October 7, 2026

Share

  • 1

    This retrospective cohort study examined VA and community emergency department use among VA-enrolled Veterans with at least 1 emergency visit in fiscal year 2023.

  • 2

    The study compared emergency department utilization and care settings by sex and assessed factors associated with women Veterans’ presentation to VA rather than community emergency departments.

  • 3

    Researchers linked VA clinical and enrollment records with community emergency care claims to characterize patient demographics, health conditions, access measures, diagnoses, and encounter outcomes.

  • 4

    Emergency encounters were classified by primary diagnosis, care setting, disposition, emergency care-sensitive conditions, behavioral health, and low acuity.

  • 5

    The study addressed limited evidence on women Veterans’ emergency care patterns across VA and community settings following expanded access to Community Care.

Original Source(s)

Where Women Veterans Seek Emergency Care: Patterns and Predictors of VA and Community Emergency Department Use

  • by Jessica Faiz, Christopher J. Carvalho, Tracy Urech, Siqi Wu, Jessica Y. Breland, Susan M. Frayne, Donna L. Washington, Kristina M. Cordasco, Anita A. Vashi

  • October 7, 2026

Related Content

Trends in alcohol-linked cancer mortality

Investigators examined 3 decades of US cancer mortality estimates across age, sex, region, and cancer type.

FDA approves combo for ESR1-mutated breast cancer

In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.

Multi-omics profiling reveals sphingolipid metabolism reprogramming of tumor-conditioned MDSCs in cervical cancer